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ABSTRACT 
BACKGROUND: Two models are mostly used to predict survival in cirrhosis, the 
Child-Pugh score (CP score) and the model for end-stage liver disease (MELD).  
AIMS: The aim of this study is to evaluate the CP score and the MELD for short and 
long-term prognosis in cirrhosis, as well as CP-creatinine, MELD-Na and UKELD. 
METHODS: 1047 patients from five referral centres were included. Men/women: 
620/427, median age: 58 years (IQR: 48-66), median follow-up:  33 months (IQR: 12-
74), CP (A/B/C):  493/357/147, CP score: 7 (IQR: 5-9), MELD: 12 (IQR: 9-16). The 
performance of each score was evaluated by the Cox hazard model in terms of their: 
discrimination ability (C-index and Sommer‟s D) and calibration (3, 12 months). 
Internal validation was done with bootstrapping (100 samples).  
RESULTS: 352 patients (33.6%) died. All scores were significantly associated with 
overall mortality, when assessed by univariate Cox analysis. CP-creatinine score 
performed significantly better than all other scores (Bootstrap C-index 0.672, 95% CI 
0.642-0.703, Bootstrap Sommer‟s D 0.344 (0.285-0.401)), apart from CP score, which 
showed similar performance. Inclusion in the multivariable Cox model of age together 
with CP-creatinine improved the discriminative ability of the model (Bootstrap C-
index (95%CI): 0.700 (0.661-0.740)). In terms of calibration, CP-creatinine was the 
best for both 3-month and 12-month survival in the total population.  
CONCLUSIONS: CP score and CP-creatinine have better prognostic value 
compared to MELD, MELD-Na and UKELD scores for predicting short and long 
term mortality in patients with stable cirrhosis. 
 
KEY WORDS: cirrhosis, liver diseases, prognosis, survival, Cox Proportional 
Hazards Models. 
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INTRODUCTION 
 Liver cirrhosis has been sub-classified in clinical stages reflecting differences in 
mortality rates [1]. Thus, a score that can accurately predict mortality is of major 
importance. Two models are mostly used in clinical practice, Child-Pugh grade/score 
(CP score) and model for end-stage liver disease (MELD). However, both were 
developed for short-term prognosis following procedures for portal hypertension, 
namely portacaval shunt for CP score [2] and transjugular intrahepatic portosystemic 
shunt (TIPS) for MELD [3].  
 Several studies have compared the performance of both scoring systems in 
predicting survival with conflicting results. In a systematic review [4] comparing the 
prognostic accuracy of MELD versus CP score, only 4 of 11 studies including 12,532 
patients showed a superiority of MELD compared to CP score in predicting 3-month 
survival. Moreover, the discriminative ability of MELD to predict mortality following 
liver transplantation was poor (concordance (c) statistic below 0.7 in all 6 studies).  
 Apart from the short-term prognostic utility, both models have limitations [5]. 
CP score has not been validated statistically and uses clinically assessed ascites and 
encephalopathy which can be influenced by subjective interpretation. On the other hand, 
MELD score needs computation and lacks the simplicity of the CP score [6]. These 
limitations have led to the development of variants of the original scoring systems, 
including MELD-Na (including serum sodium, a significant predictor of early mortality 
and indirect indicator of the presence of ascites) [7, 8], and CP-creatinine (which 
includes renal function in order to increase its predictive accuracy) [9].  
 We conducted this multicentre cohort study to evaluate MELD, CP score, 
MELD-Na, CP-creatinine and United Kingdom End-stage Liver disease (UKELD) 
scores as prognostic models for long-term prognosis as well as for 3-, 6-, and 12-
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monthsurvival in patients with stable cirrhosis taking into consideration the conflicting 
results in the literature. 
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PATIENTS AND METHODS 
 
Study population 
 
  This is a multicentre retrospective cohort study including consecutive 
outpatients with cirrhosis between1974 and 2012 in five referral centres: a) Department 
of Gastroenterology, University Hospital, Patras, Greece (n=496), b) The Royal Free 
Sheila Sherlock Liver Centre, Royal Free Hospital and University College School of 
Medicine, London, UK (n=341), c) 4th Department of Internal Medicine, Hippokration 
General Hospital of Thessaloniki, Medical School of Aristotle University, Greece 
(n=104). d) 2nd Academic Department of Internal Medicine, University of Athens, 
Hippokration General Hospital, Athens, Greece (n=102) and e) Department of 
Gastroenterology, Polyclinic General Hospital, Athens, Greece (n=92). The included 
patients were recruited from the hepatology clinics of the physicians that participated in 
the study. The study was compliant with the ethical standards of the Declaration of 
Helsinki. There were 1135 patients with cirrhosis. Patients with hepatocellular 
carcinoma (HCC) (n=78) at baseline and those with no information on any of the 
prognostic scores under investigation (n=10) were excluded from the analysis. None of 
the patients had concomitant human immunodeficiency virus (HIV) infection. The study 
cohort finally included 1047 patients.  
Diagnosis of cirrhosis was based on clinical, laboratory and previous 
radiological and histological findings. The management according to etiology of 
cirrhosis was based on international practice guidelines [10-13]. None of the patients 
with HCV cirrhosis had sustained virological response before enrolment. In patients 
enrolled before 1990, diagnosis of HCV infection was documented later and these 
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patients were included in the „HCV etiology‟ cohort or in „other etiology‟ cohort, if 
HCV seropositivity was not confirmed. Medical history, physical examination and 
laboratory tests were available in all patients at their first admission. The definitions of 
diabetes mellitus, chronic kidney disease, hypertension, ischemic heart disease and 
chronic respiratory diseases (including chronic obstructive pulmonary disease, asthma, 
obstructive sleep apnea syndrome, bronchiectasis, pulmonary hypertension) were based 
on the workup of the attending physician according to the current internationally 
accepted guidelines. Patients were followed-up by experienced hepatologists until 
death, liver transplantation, study closure or last contact with the health system. The 
management of moderate/severe ascites, spontaneous bacterial peritonitis, hepatorenal 
syndrome, hepatic encephalopathy and acute variceal bleeding was according to the 
international practice guidelines as published at the time of enrolment. The final status 
(alive, transplanted, death) was recorded. 
End-points and definitions 
The primary end-point was the comparison of the prognostic accuracy of the 
different models regarding mortality at 3, 6 and 12 months and at the end of follow-up.  
We also performed a subgroup analysis for different aetiologies of liver disease and for 
patients with MELD≥ 15. CP score, MELD, MELD-Na and UKELD were assessed as 
previously described [2, 14-17] . CP-creatinine was calculated as CP score + 1, 2 or 3 (if 
creatinine<1.3, 1.3-1.5 and ≥1.5 mg/dl, respectively) [9]. Regarding PBC patients, the 
Mayo risk score [18] and the Royal Free score [19] were also calculated; CP score was 
assessed as suggested by Pugh et al [2]. Only PBC patients with histological staging of 
3 and 4 were included [20].  
 
9 
 
Statistical Analysis 
Categorical characteristics were summarized as counts and corresponding 
percentages, while medians and interquartile ranges (IQRs) were given for the 
continuous characteristics. Predictors of overall survival were evaluated using Cox 
proportional hazards models.  Patients were censored at the last follow-up date or at the 
date of liver transplantation. The discrimination ability of each proposed prognostic 
score was assessed by both the C-index and the Sommer‟s D [21]. To adjust for 
overfitting, our results were internally validated with bootstrapping [22, 23]. 
Comparisons of the c-index across  different models were performed using non-
parametric tests [24]. As a second aspect of models‟ validity, the calibration plots at 3 
and 12 months were presented [25]. 
For illustration, dynamic/incident Receiver-operating curve (ROC) suitable for 
survival data is presented at 3, 6 and 12 months of follow-up using the risk-set package 
in R, based on previously published work [26]. 
To account for known confounders, all scores were evaluated separately in 
multivariable models adjusted for age, sex, ischemic heart disease, total bilirubin, 
creatinine, sodium, INR, albumin, encephalopathy and ascites. The variables were 
adjusted depending on the components of the scores, excluding factors incorporated into 
the definition of the score; for instance, sodium, INR, bilirubin and creatinine were not 
included in the model when MELD-Na was evaluated. 
Several sensitivity analyses were carried out: a) to account for potential 
differences across centers, analysis was repeated after including the different centers in 
both the univariable and multivariable models; b) subgroup analyses among those with 
and without decompensation as well as among those with and without anti-HBV 
treatment were performed. All analyses were performed with Stata11.2.  
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Institutional review board statement 
The study was reviewed and approved by the Ethics committee of University Hospital 
of Patras. 
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RESULTS 
A total of 1047 patients were included in the analysis. Patients‟ characteristics 
are presented in Table 1. Patients were followed-up for a median of 33 months (IQR 
12-74). Fifty-nine deaths were observed within the first 3 months and 121 deaths 
within the first year of follow-up. During the entire follow-up, 352 patients (33.6%) 
died and 42 (4%) patients were transplanted. 
 
Comparison of the predictive models (CP, CP-creatinine, MELD, MELD-Na and 
UKELD) for 3-, 6-, 12-month and overall survival 
 
Total Population 
 Discrimination measures as estimated in the original sample did not differ 
substantially from the corresponding bootstrap estimates, indicating low overfitting. 
CP-creatinine score performed overall better than the other examined scores 
(bootstrap C-index: 0.672, 95% CI: 0.642-0.703, bootstrap Sommer‟s D: 0.344 
(0.285-0.401)) (Table 2) but this difference was not significant when compared to CP 
score. Subgroup analysis showed that all scores performed better in patients with 
compensated compared to those with decompensated cirrhosis, although the CP-
creatinine score performed overall better than the other examined scores, as in the 
main analysis (Suppl. Table 1). The C-indexes of CP score and CP-creatinine scores 
were significantly higher compared to MELD, MELD-Na or UKELD scores (Table 
3). Sensitivity analysis after inclusion of the centers together with each predictive 
score in a model yielded similar results (data not shown). 
The dynamic/incident Receiver Operating Characteristic (ROC) curves of CP 
score, CP-creatinine, MELD, MELD-Na and UKELD score for 3-month, 6-month and 
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12-month survival are shown in Figure 1 (a-c). CP-creatinine and CP scores had the 
best discriminative ability for all time points. Nevertheless, given that the C-index 
was relatively low in all cases (a C-index equal to 0.5 is expected by chance and the 
Somer‟s D was well below 1), the discrimination ability of all prognostic scores was 
moderate to low. 
 
Patients with alcoholic, viral cirrhosis and MELD score ≥ 15 
In the subgroup analysis of patients with alcoholic and viral cirrhosis, the results 
were the same as in the total population, with CP-creatinine and CP score performing 
better than the other prognostic scores (bootstrap C-index (95% CI): 0.630 (0.579-
0.681) and 0.626 (0.569-0.684), respectively for alcoholic cirrhosis, and 0.691 (0.652-
0.730) and 0.688 (0.643-0.732), respectively for viral cirrhosis) (Suppl. Table 2). In 
patients with MELD score ≥15, CP-creatinine score performed overall better than the 
other scores with a bootstrap C-index of 0.632 (95%CI: 0.576-0.688) (Suppl. Table 
2). The comparison of the C-indexes between the scores for the subgroup analyses is 
shown in Suppl. Table 3. A separate analysis was performed for patients with HBV 
cirrhosis to explore if there were any differences in the prognostic accuracy of the 
scores between patients included in the study before and after the year 2000 in order 
to assess their performance before and after the era of nucleot(s)ide analogues. No 
differences were observed (data not shown). However, when data was divided 
according to anti-HBV therapy, all scores performed better in patient treated for HBV 
compared to untreated patients, but the order of the relative performance was similar 
to that of the main analysis (Suppl. Table 4). 
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Predictive factors for overall survival 
Univariable analysis 
Univariate analysis using Cox proportional hazards model showed that 
advanced age, male sex, ischemic heart disease at baseline, INR, total bilirubin, 
albumin, creatinine, sodium, encephalopathy and ascites at baseline were significantly 
associated with survival (Suppl. Table 5). Moreover, all the prognostic models (CP 
score, CP-creatinine, MELD, MELD-Na and UKELD) were significantly associated 
with overall mortality (Table 2). 
 
Multivariable analysis 
Total Population 
Multivariate Cox regression analysis for overall survival including all 
significant baseline characteristics together with each prognostic score is shown in 
Suppl. Table 6. Inclusion in the Cox model of age together with CP-creatinine score 
improved the discrimination ability of the model substantially (bootstrap C-index 
(95%CI): 0.700 (0.661-0.740)). Similarly, inclusion of age, albumin and ascites 
together with MELD-Na (or UKELD) score increased the C-index and Somer‟s D of 
MELD-Na (or UKELD) score (bootstrap C-index (95%CI): 0.699 (0.663-0.735) and 
0.698 (0.662-0.733), respectively). Sensitivity analysis after inclusion of the centers in 
all the aforementioned multivariable analyses yielded similar results (data not shown).  
In all cases, differences between naïve and bootstrap estimates were small, 
indicating that optimism was negligible in all cases. There were no differences 
between the C-indexes derived by the multivariable models for all prognostic scores 
of interest (Suppl. Table 7).   
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Patients with viral, alcoholic cirrhosis and MELD score ≥ 15 
When the same analysis was performed in patients with viral cirrhosis, the 
results were similar to the abovementioned with age being significant for CP-
creatinine, and albumin, age and ascites for MELD-Na (or UKELD). In the subgroup 
analysis of patients with alcoholic cirrhosis and in those with MELD ≥15, age was the 
only factor found statistically significant for all prognostic scores (data not shown). 
 
Primary Biliary Cirrhosis (PBC) 
 
Comparison of the predictive models (CP, CP-creatinine, MELD, MELD-Na, 
UKELD, PBC-RFH and Mayo Risk score) for 3-, 6-, 12-month and overall survival 
 
 UKELD score had excellent predictive accuracy (C-index > 0.8) (bootstrap C-
index 0.828, 95% CI 0.733-0.923, bootstrap Sommer‟s D 0.344 (0.285-0.401)), 
followed by Mayo Risk score (bootstrap C-index (95%CI): 0.794 (0.683-0.906)) and 
PBC RFH score (bootstrap C-index (95%CI): 0.784 (0.682-0.887)). CP, CP-creatinine 
and MELD had the lowest performance (Table 4). The comparison of the C-indexes 
between scores showed that UKELD, PBC RFH and Mayo risk scores had 
significantly higher diagnostic accuracy compared to CP score. The dynamic/incident 
ROC curves of CP, CP-creatinine, MELD, MELD-Na, UKELD, Mayo Risk and PBC 
RFH scores for 3-month, 6-month and 12-month survival in patients with PBC are 
shown in Figure 2 (a-c). UKELD had the highest discriminative ability for 3-month 
and 6-month survival, but in 12 months PBC RFH and Mayo Risk scores performed 
better than all other scores.  
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Predictive factors for overall survival 
 All prognostic scores were associated with overall mortality in the univariable 
analysis. Results from multivariable Cox regression analysis including all significant 
baseline characteristics together with each prognostic score are shown in Suppl. Table 
8. Age was the only factor that was statistically significant for all prognostic scores, 
apart from Mayo Risk and PBC RFH scores which already incorporate age. The 
addition of age in the Cox multivariable model increased the C-index and the Somer‟s 
D of each predictive score (Suppl. Table 8). Regarding PBC RFH and Mayo Risk 
scores, creatinine was independently associated with overall survival. Male sex was 
also independently associated with worse survival when tested together with PBC 
RFH score. The comparison between the C-indexes of each multivariable model 
showed no statistical significance, apart from MELD-Na/Age model that was found 
significantly better than CP-creatinine/age model (bootstrap C-index (95%CI): 0.96 
(0.896-1.02) and 0.897 (0.794-1.001), respectively) (Suppl. Table 8). 
 
Calibration 
 Calibration between observed and predicted survival probabilities was good in 
the majority of the models, both at 3 and 12 months. The CP-creatinine score 
demonstrated the best calibration (Suppl. Figures 1a-l) when tested in the total 
population.   
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DISCUSSION 
The present study clearly demonstrates the superiority of CP and CP-creatinine 
scores to predict both short and long-term survival in a large population of outpatients 
with cirrhosis compared to MELD, MELD-Na or UKELD scores. The main 
advantage of this study is that it takes into account other chronic diseases such as 
ischemic heart disease or diabetes mellitus that might independently affect mortality. 
The incorporation of age increased the predictive accuracy of the models. Advanced 
age is associated with a longer duration of chronic liver disease, reduced cellular 
regeneration and immune surveillance and there is data supporting its prognostic 
significance [1, 27].  
The advantages of MELD score lie in the statistically weighted “markers” and 
the inclusion of creatinine [5], while CP score is a simple score without need for 
complex computations [5].  However, while CP score weighs all variables equally, 
MELD weighs them in a non-linear fashion. The performance of MELD and CP score 
has been compared with conflicting results [28-30]. The majority of the studies that 
included patients undergoing TIPS placement showed an equal performance for 3-
month and 12-month mortality apart from a study by Salerno et al [28] in which 
MELD performed significantly better than CP score for 3-month mortality [31]. In the 
studies that included patients without TIPS placement, the predictive accuracies of the 
MELD and CP scores were equal, with higher performance at 3 and 6 months and 
progressively lower at longer time-periods [27, 31]. In the present study, CP and CP-
creatinine had a significantly higher predictive accuracy than MELD or MELD-Na 
scores for overall mortality. The discrepancies between our study and the study by 
Said et al [27] can be related to the lower proportion of HCV and higher proportion of 
PBC patients, to the inclusion of outpatients, to the longer follow-up period and the 
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lower incidence of patients undergoing liver transplantation in our study. However, 
our findings are consistent to those reported by D‟Amico et al [1].  
Since no renal parameter was taken into account in the original CP score, a 
modified CP score including serum creatinine as a dichotomous variable was 
developed [32]. In the study by Angermayer et al [32], the c-statistics for 3-month 
survival for CP score, MELD and CP score-creatinine, in patients undergoing TIPS 
were similar. In contrary, Giannini et al [33] found that in the prediction of 3-month 
mortality, the c-statistic of MELD (0.947) was marginally better compared to CP 
score-creatinine, but significantly higher compared to CP score (0.757). 
Papatheodoridis et al [9] evaluated the predictive value of CP score, MELD and 
creatinine-modified CP score in 102 patients with decompensated cirrhosis. The 
AUROCs for 3, 6, 12 and 24-month mortality did not differ significantly among the 
four scores. In a recent publication, Kaplan et al adjusted CP score outpoints to 
improve predictive capacity and evaluated a modified CP-creatinine score [34]. They 
concluded that the modified CP score and creatinine-modified CP score models 
showed superiority over the original CP score and MELD in predicting 1-, 2-, 3-, 4- 
and 5-year transplant-free survival [34]. In our study, which included both 
compensated and decompensated cirrhotics, the addition of creatinine in CP score did 
not significantly improve its accuracy. When we divided our patients in two groups 
(with and without decompansation) and performed subgroup analysis, it had been 
shown that all scores performed better in patients without decompensation compared 
to those with compensated cirrhosis, although the CP-creatinine score performed 
better. These discrepancies might reflect the differences in the study populations, the 
cut-offs used for creatinine, the length of follow-up periods and the variations in 
creatinine measurements among different laboratories. It seems that the superiority of 
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MELD score in patients awaiting for liver transplantation [15] relies on the fact that 
this cohort has renal impairment [35]. Apparently, creatinine has little impact in the 
non-transplant setting and in stable cirrhosis. 
It has been suggested that the inclusion of other factors to the original MELD 
may offer additional prognostic value [5, 15, 32, 36, 37]. Although mortality rates in 
patients with cirrhosis who develop complications are higher [38-40], MELD score 
fails to predict this impact on survival [1]. It has been suggested [8] that the addition 
of serum sodium to MELD can improve its accuracy [41, 42]. In the present study no 
differences were observed between the prognostic performances of MELD and 
MELD-Na or UKELD similarly to the study by Boursier et al [29]. Londono et al [43] 
found that MELD score and serum sodium concentration were the only independent 
predictors of 3-month and 12-month survival, but the addition of serum sodium did 
not significantly improve its accuracy. We did not observe independent associations 
between serum sodium and overall mortality.  
In the present study, the performance of models predicting long-term survival 
was poor compared to other studies [29, 36]. However, the prognostic performance of 
both MELD and CP score is lessened over time [28]. 
Cirrhosis is a dynamic entity [44] and  repeated assessment of scoring systems 
is needed [27]. In patients with MELD≥15, a superiority of CP score-creatinine was 
observed. This MELD cut-off was used considering that a major change in survival 
probability occurs at this threshold [45]. Most importantly, the incorporation of 
creatinine as a trichotomous variable in CP score seems to have a higher performance 
for long-term survival compared to its inclusion in MELD score as a continuous 
variable in high risk patients.  
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The data on the impact of etiology of liver disease is scarce. The original MELD 
[3] incorporated etiology, but it was removed later when Kamath et al [37] showed 
that etiology had a little impact on its accuracy [15]. In our study, in patients with 
viral and alcoholic etiology, CP-creatinine and CP scores had the highest predictive 
accuracy as in the total population. The performance of MELD, MELD-Na and 
UKELD was better in viral, compared to alcoholic cirrhosis. This suggests that in 
patients with alcoholic cirrhosis other factors such as active alcohol drinking 
contribute to long-term mortality.  
Another important observation is that, in HBV cirrhosis, all scores performed 
equally irrespective of the year of enrollment, i.e. before or after the year 2000, when 
anti-HBV treatment with lamivudine was initiated. This implies that the models have 
equal diagnostic accuracy independent to the initiation of antiviral treatment. 
Moreover, when we divided the patients in two groups according to the receipt or not 
of anti-HBV therapy, all scores performed better in patient treated for HBV compared 
to untreated patients, however the order of the relative performance was similar to that 
of the main analysis. 
In patients with PBC, UKELD, Mayo Risk and RFH-PBC scores had excellent 
and equal accuracy to predict long-term mortality and they performed significantly 
better compared to CP, MELD and their modified versions. In our knowledge, this is 
the first study to confirm the excellent performance of UKELD in PBC patients 
during a long follow-up period. In ROC curve analysis, the UKELD performance was 
better for the prediction of 3- and 6-month survival, while the Mayo Risk and RFH-
PBC scored better for the 12-month mortality risk. This is not surprising considering 
that UKELD was developed specifically for patient awaiting liver transplantation in a 
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short-term follow-up, whereas the other two scores were built to predict 24-month 
mortality.  
The present study is subject to certain limitations. Firstly, it has a 
retrospective/prospective design. However, all variables were collected prospectively 
by experienced physicians in well-organized medical databases. There were few 
missing values and our results are consistent to those observed by others [29]. 
Secondly, we included a large number of patients with PBC who have a survival 
benefit compared to alcoholic or viral-related cirrhotics [46]. However, PBC patients 
have been included in many other similar studies [9, 37, 47]. Thirdly, there was a 
small number of transplanted  patients in our cohort compared to other studies [27]. 
However, due to the small number of liver transplant centers in Greece and the high 
demand for organs, a large number of patients will not be eventually transplanted. 
Thus, our results have also important implications in liver centers with no 
transplantation facilities. The confounding probability related to the various 
differences among the hospitals (standard of care, different distribution of disease 
etiology, differences in the laboratory tests used, time period of recruitment) was 
addressed in a sensitivity analysis. All conclusions regarding the effect of the 
prognostic scores in terms of hazard ratios, as well as their predictive ability in terms 
of C-indexes, remained intact indicating no confounding probability. Another 
limitation of this study is that we included only baseline characteristics as predictive 
factors of survival in order to reach conclusions useful in the everyday clinical 
practice and to avoid bias related to missing values.  
In conclusion, CP score and CP-creatinine are superior to MELD, MELD-Na 
and UKELD for the prediction of short-term and long-term mortality. Although CP 
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score is likely to need statistical validation, it should not be abandoned in clinical 
practice. 
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Table 1. Baseline characteristics of study population. 
Sex (M/F), n (%) 620/427 (59.2/40.8) 
Age (years), median (IQR) 58 (48, 66) 
Cause of liver disease, n (%)  
HBV±HDV 141 (13.5) 
HCV 128 (12.2) 
Alcohol 347 (33.1) 
PBC 151 (14.4) 
PSC 2 (0.2) 
AIH 56 (5.3) 
HBV±HDV/HCV 10 (1) 
HBV±HDV +Alcohol 44 (4.2) 
HCV+Alcohol 54 (5.2) 
HBV±HDV/HCV + Alcohol 4 (0.4) 
Other 110 (10.5) 
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Diabetes mellitus, n (%) 176 (16.8) 
Ischemic heart disease, n (%) 57 (5.4) 
Chronic respiratory diseases, n (%) 46 (4.4) 
Hypertension, n (%) 152 (14.5) 
Smoking, n (%) 283 (27.0) 
INR, median (IQR) 1.3 (1.1, 1.5) 
Total bilirubin (mg/dl), median (IQR) 1.6 (0.9, 3.1) 
Albumin (g/dl), median (IQR) 3.5 (3.0, 3.9) 
Urea (mg/dl), median (IQR) 30.5 (20.0, 41.0) 
Creatinine (mg/dl), median (IQR) 0.9 (0.7, 1.0) 
Sodium (mmol/L), median (IQR) 139.0 (136.0, 141.0) 
Encephalopathy, n (%) 281 (26.8) 
Ascites, n (%) 318 (30.4) 
CP score, median (IQR) 7.0 (5.0, 9.0) 
CP A/B/C, n (%) 493/357/147 (47.1/34.1/14) 
CP score  -creatinine, median (IQR) 7.0 (5.0, 9.0) 
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MELD, median (IQR) 12.0 (9.0, 16.0) 
MELD-Na, median (IQR) 14.0 (10.0, 20.0) 
UKELD score, median (IQR) 52.0 (49.0, 57.0) 
PBC Mayo risk score, median (IQR) 7.0 (5.8, 8.4) 
PBC Royal Free Hospital Score -1.0 (-1.9, -0.1) 
M/F: male/female, PBC: primary billiary cirrhosis, PSC: primary sclerosing cholangitis, AIH: autoimmune hepatitis, INR: 
International normalized ratio, CP score: Child-Pugh score, CP: Child-Pugh class, MELD: Model for End-stage Liver Disease, 
UKELD: United Kingdom End-stage Liver Disease, IQR: interquartile range. 
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Table 2. Results based on the Cox proportional hazards models including the scores under investigation as the only predictor of survival 
in the total sample size. Hazard ratio estimates are based on the whole dataset. Discrimination measures, i.e C-index and Sommer’s D 
were estimated a) using the whole sample (i.e naïve) and b) as the average of 100 bootstrap samples.  
 
 
 
Median (IQR) HR (95% CI) p value 
C-index Somer's D 
Naïve (95% CI) Bootstrap (95% CI) Naïve (95% CI) Bootstrap (95% CI) 
Child-Pugh 7.0 (5.0, 9.0) 1.26 (1.20-1.32) <0.001 0.667 (0.637-0.697) 0.664 (0.633,0.694) 0.333 (0.270-0.397) 0.329 (0.266-0.392) 
Child-Pugh + 
Creatinine 
7.0 (5.0, 9.0) 1.24 (1.19-1.29) <0.001 0.673 (0.642- 0.703) 0.672 (0.642-0.703) 0.345 (0.288-0.401) 0.344 (0.879-0.401) 
MELD 12.0 (9.0, 16.0) 1.08 (1.06, 1.10) <0.001 0.643 (0.613-0.673) 0.643 (0.613,0.674) 0.286 (0.220-0.351) 0.285 (0.220-0.351) 
MELD + Na 14.0 (10.0, 20.0) 1.07 (1.05-1.09) <0.001 0.623 (0.588-0.658) 0.625 (0.591-0.660) 0.246 (0.178-0.313) 0.246 (0.178-0.314) 
UKELD 52.0 (49.0, 57.0) 1.06 (1.04-1.08) <0.001 0.605 (0.568-0.641) 0.605 (0.568-0.642) 0.209 (0.139-0.279) 0.208 (0.138-0.279) 
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Table 3. Comparison (p-values) between the c- indexes of the different prognostic scores regarding overall survival in the total 
population. 
 Child-Pugh Child-Pugh+ Creatinine MELD MELD + Na UKELD 
Child-Pugh -     
Child-Pugh+ Creatinine 0.203 -    
MELD 0.033 0.001 -   
MELD + Na 0.026 0.001 0.764 -  
UKELD 0.001 <0.001 0.090 0.054 - 
MELD: Model for end-stage liver disease, UKELD: United Kingdom End-stage Liver Disease.  
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Table 4. Results based on the Cox proportional hazards models including the scores under investigation as the only predictor of survival 
in patients with primary biliary cirrhosis (PBC). Hazard ratio estimates are based on the whole dataset. Discrimination measures, i.e C-
index and Sommer’s D were estimated a) using the whole sample (i.e naïve) and b) as the average of 100 bootstrap samples. 
PBCN=151  C-index Somer's D 
Score HR (95% CI) p naive (95% CI) bootstrap (95% CI) naive (95% CI) bootstrap (95% CI) 
Child-Pugh score 1.56 (1.18-2.06) 0.004 0.660 (0.532-0.798) 0.658 (0.525-0.791) 0.330 (0.078-0.581) 0.331 (0.079-0.582) 
CP-creatinine score 1.58 (1.24-2.00) <0.001 0.670 (0.560-0.789) 0.687 (0.573-0.802) 0.349 (0.071-0.628) 0.349 (0.070-0.627) 
MELD score 1.15 (1.06-1.24) 0.003 0.690 (0.536-0.835) 0.683 (0.533-0.833) 0.371 (0.081-0.661) 0.371 (0.080-0.661) 
MELD-Na score 1.23 (1.11-1.38) <0.001 0.760 (0.571-0.959) 0.753 (0.559-0.947) 0.530 (0.158-0.901) 0.548 (0.176-0.920) 
UKELD model 1.19 (1.09-1.29) <0.001) 0.830 (0.732-0.922) 0.828 (0.733-0.923) 0.654 (0.444-0.864) 0.655 (0.445-0.866) 
RFH 2.45 (1.71-3.52 <0.001) 0.780 (0.681-0.887) 0.784 (0.682-0.887) 0.568 (0.341-0.795) 0.582 (0.355-0.809) 
Mayo risk score 1.87 (1.43-2.43) <0.001 0.790 (0.678-0.902) 0.794 (0.683-0.906) 0.580 (0.359-0.801) 0.573 (0.353-0.794) 
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Table 5. Comparison (p-values) between the c- indexes of the different prognostic scores regarding overall survival in patients with 
Primary Biliary Cirrhosis. 
 Child-Pugh Child-Pugh+ Creatinine MELD MELD+Na UKELD RFH score Mayo risk score 
Child-Pugh -       
Child-Pugh + Creatinine 0.361 -      
MELD 0.102 0.063 -     
MELD+Na 0.120 0.105 0.473 - 
   
UKELD 0.049 0.251 0.802 0.687 -   
RFH score 0.019 0.174 0.494 0.436 0.444 -  
Mayo risk score 0.030 0.173 0.527 0.463 0.477 0.612 - 
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Figure 1. Dynamic/incident ROC curves of Child-Pugh, Child-Pugh creatinine, 
MELD, MELD-Na and UKELD score for a) 3-month, b) 6-month and c) 12-month 
survival in the total population.  
 
Figure 2. Dynamic/incident ROC curves of Child-Pugh, Child-Pugh creatinine, 
MELD, MELD-Na and UKELD score for a) 3-month, b) 6-month and c) 12-month 
survival in patients with Primary Biliary Cirrhosis. 
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